Spinout Active LTD

Company profile

Edinburgh Molecular Imaging Limited

Emimaging - Edinburgh Molecular Imaging | Edinburgh Molecular Imaging | See. Treat. Cure.

Edinburgh Molecular Imaging Limited is a UK company with status active founded in 2014 based in Scotland.

CRN
SC467269
Founded
2014
Age
12

Overview

Browse spinouts
Legal name
EDINBURGH MOLECULAR IMAGING LIMITED
Region
Scotland
Registered address
137A GEORGE STREET
EDINBURGH
SCOTLAND
EH2 4JY
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Edinburgh Molecular Imaging Limited
CRN SC467269
2
Direct and ultimate controller
SL11942
CRN SL11942

Company events

Reference milestones and recent Companies House filing stream events.

5 events
27 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Oct
2026

Accounts due

Accounts Due

Next accounts due date

13 Jan
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jan
2025

Accounts filed

Accounts

Last accounts made up date

13 Jan
2014

Incorporated

Inception

Company registered at Companies House

Spinout profile

1 entry

Company description

SME that is focussing on Optical Molecular Imaging and the rapid commercialisation of in vivo optical imaging agents for human disease

Project impact

Raised £4M Series A. Awarded Innovate UK award.

Edinburgh Molecular Imaging
2014

Public funding

2 awards
First funded
2016
Funded years
2016, 2017
Age at first award
2 years

Projects

2017 EU-Funded Lead participant

Novel c-Met Protein Targeted Molecular Imaging of Cancer with the SurgVision Endoscope Explorer

1 Dec 2017 to 30 Nov 2019

Awarded
£296,516
Total cost £494,194

To deliver a revolutionary optical cancer screening solution that combines a unique biomarker with a novel imaging device, addressing a significant gap associated with current screening methods (high cancer miss rates, poor visualisation). Project outputs will determine which of a number of possible indications to take forward to full stage clinical trial...

2016 Small Business Research Initiative Lead participant

Enhanced in-vivo screening and molecular analysis for colorectal cancer

1 Mar 2016 to 30 Nov 2016

Awarded
£149,997
Total cost £149,997

Abstract: Colorectal Cancer (CRC), also known as bowel cancer, is the third most common cancer diagnosed in men and second most common cancer in women, affecting 1,361,000 people worldwide each year. It is also the second most common cause of cancer related deaths, contributing to 737,000 deaths every year (Globocan, 2012). CRC is a slow growing tumour th...

Product types

EU-Funded Small Business Research Initiative